Clinical program expanded to include adolescents

AD-1526

A multicenter, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of DUPIXENT® monotherapy in 251 adolescent AD patients (12 to 17 years old) as monotherapy for 16 weeks1†

Patient demographics1

14.5 years - mean age

59.4 kg - median weight

41% - female

63% - white

15% - Asian

12% - black

92% - had at least one co-morbid allergic condition

66% - allergic rhinitis

54% - asthma

61% - food allergy

Disease severity at baseline1

46% IGA score of 3 (moderate AD)

54% IGA score of 4 (severe AD)

57% mean BSA involvement

42% received prior systemic immunosuppressants

36 mean EASI score

8/10 weekly averaged peak pruritus NRS

AD-1434

An open-label extension trial investigating the long-term efficacy of DUPIXENT® in adolescent patients who had participated in previous clinical trials of DUPIXENT® for up to 52 weeks1

Q2W: every 2 weeks
† Patients received an initial dose of 400 mg at Week 0, followed by 200 mg Q2W for subjects with baseline weight of <60 kg or an initial dose of 600 mg at Week 0, followed by 300 mg Q2W for subjects with baseline weight of ≥60 kg. DUPIXENT® was administered by subcutaneous injection. If needed to control intolerable symptoms, subjects were permitted to receive rescue treatment at the discretion of the investigator. These patients were considered non-responders.1



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo